Buy Rating for Philip Morris: Strategic Positioning and FDA Approval of ZYN Pouches
Analyst Lisa Lewandowski from Bank of America Securities maintained a Buy rating on Philip Morris (PM – Research Report) and keeping the price ...
Morgan Stanley sets Philip Morris stock target, overweight on portfolio
Morgan Stanley (NYSE:MS) initiated coverage on shares of Philip Morris International Inc. (NYSE:NYSE:PM) shares, bestowing an Overweight rating and establishing a price target of $140. The move ...
Philip Morris Gains Competitive Edge with FDA Authorization of ZYN Nicotine Pouches
Analyst Matthew Smith of Bank of America Securities maintained a Buy rating on Philip Morris (PM – Research Report), with a price target of ...
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
Federal health officials are backing the health benefits of nicotine pouches, ruling that Philip Morris International's Zyn ...
FDA Allows Flavored Zyn Nicotine Pouches to Stay on the Market
The agency found Zyn’s benefit as a safer alternative for adult cigarette smokers outweighs its risk to young people.
Philip Morris: Shift To Smoke-Free Sparks Steady Dividend Growth
Learn how Philip Morris International plans to shift to smoke-free products by 2030 to mitigate risks, boost profits, and ...
Philip Morris Shares Advance 1% After FDA Authorizes Marketing of Zyn
Philip Morris International shares edged up slightly after the Food and Drug Administration authorized marketing for 20 Zyn nicotine-pouch products. The stock rose about 1%, to $119.40, late Thursday ...